Robert S. Rosenson

1.3k total citations · 2 hit papers
26 papers, 961 citations indexed

About

Robert S. Rosenson is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Robert S. Rosenson has authored 26 papers receiving a total of 961 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cardiology and Cardiovascular Medicine, 14 papers in Endocrinology, Diabetes and Metabolism and 12 papers in Surgery. Recurrent topics in Robert S. Rosenson's work include Lipoproteins and Cardiovascular Health (11 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (11 papers) and Lipid metabolism and disorders (8 papers). Robert S. Rosenson is often cited by papers focused on Lipoproteins and Cardiovascular Health (11 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (11 papers) and Lipid metabolism and disorders (8 papers). Robert S. Rosenson collaborates with scholars based in United States, Canada and Australia. Robert S. Rosenson's co-authors include Daniel Gaudet, Michael H. Davidson, Benjamin J. Hirsh, Sekar Kathiresan, Harold Bays, Lawrence Blonde, Carlos G. Santos‐Gallego, Gerald F. Watts, Paul Muntner and Kausik K. Ray and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of the American College of Cardiology.

In The Last Decade

Robert S. Rosenson

20 papers receiving 935 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk

2024 66 citations Gerald F. Watts, Robert S. Rosenson et al. New England Journal of Medicine profile →
Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial

2025 16 citations Kausik K. Ray, Robert S. Rosenson et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert S. Rosenson United States	13	525	368	359	142	139	26	961
Sephy Philip United States	18	569 1.1×	557 1.5×	367 1.0×	96 0.7×	125 0.9×	57	1.1k
Daniel M Hoefner United States	12	676 1.3×	512 1.4×	309 0.9×	224 1.6×	121 0.9×	21	1.1k
Eliscer Guzman United States	17	374 0.7×	337 0.9×	256 0.7×	119 0.8×	183 1.3×	28	1.0k
Michael J. Blaha United States	18	521 1.0×	349 0.9×	210 0.6×	128 0.9×	82 0.6×	44	881
Michael V. Holmes United Kingdom	16	361 0.7×	255 0.7×	389 1.1×	99 0.7×	117 0.8×	25	1.2k
Brian T. Steffen United States	19	613 1.2×	315 0.9×	386 1.1×	159 1.1×	140 1.0×	47	1.2k
David Colquhoun Australia	11	631 1.2×	341 0.9×	341 0.9×	143 1.0×	125 0.9×	16	1.1k
Tomáš Štulc Czechia	16	567 1.1×	263 0.7×	198 0.6×	125 0.9×	100 0.7×	58	1.0k
Melchior C. Nierman Netherlands	15	357 0.7×	325 0.9×	542 1.5×	80 0.6×	133 1.0×	32	1.1k
Douglas Kling United States	13	596 1.1×	368 1.0×	350 1.0×	129 0.9×	166 1.2×	36	1.3k

Countries citing papers authored by Robert S. Rosenson

Since Specialization

Citations

This map shows the geographic impact of Robert S. Rosenson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert S. Rosenson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert S. Rosenson more than expected).

Fields of papers citing papers by Robert S. Rosenson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert S. Rosenson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert S. Rosenson. The network helps show where Robert S. Rosenson may publish in the future.

Co-authorship network of co-authors of Robert S. Rosenson

This figure shows the co-authorship network connecting the top 25 collaborators of Robert S. Rosenson. A scholar is included among the top collaborators of Robert S. Rosenson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert S. Rosenson. Robert S. Rosenson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ray, Kausik K., Robert S. Rosenson, Jeremiah Jones, et al.. (2025). Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. 405(10489). 1594–1607. 16 indexed citations breakdown →

Watts, Gerald F., Robert A. Hegele, Robert S. Rosenson, et al.. (2025). PALISADE: PLOZASIRAN DECREASES THE RISK OF ACUTE PANCREATITIS AND MAY IMPROVE QUALITY OF LIFE IN FAMILIAL CHYLOMICRONEMIA SYNDROME. American Journal of Preventive Cardiology. 23. 101140–101140.

Rosenson, Robert S., et al.. (2025). Digenic Overlap Syndrome Masquerading as Homozygous Familial Hypercholesterolemia. JACC Case Reports. 30(18). 104036–104036.

Rosenson, Robert S., J. Antonio G. López, Daniel Gaudet, et al.. (2025). Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers. JAMA Cardiology. 10(5). 482–482. 13 indexed citations

Watts, Gerald F., Robert S. Rosenson, Robert A. Hegele, et al.. (2024). Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. New England Journal of Medicine. 392(2). 127–137. 66 indexed citations breakdown →

Vasas, Szilárd, Masoud Azizad, Peter Clifton, et al.. (2024). †Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Robust and Durable TG Reductions in Patients with Mixed Dyslipidemia, MUIR Final Results. Journal of clinical lipidology. 18(4). e560–e560.

Páll, Dénes, Gerald F. Watts, Stephen C. Nicholls, et al.. (2024). †Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Deep and Durable TG Reductions in Patients With SHTG, SHASTA-2 Final Results. Journal of clinical lipidology. 18(4). e564–e564. 1 indexed citations

Peterson, Benjamin E., Deepak L. Bhatt, Christie M. Ballantyne, et al.. (2024). Inadequate Intensification of LDL-cholesterol lowering therapy after coronary revascularization: Insights from the GOULD registry. International Journal of Cardiology. 421. 132916–132916.

Rosenson, Robert S., Daniel Gaudet, Robert A. Hegele, et al.. (2024). Zodasiran silences hepatic ANGPTL3 leading to deep and durable reductions in atherogenic lipids and lipoproteins in mixed dyslipidemia patients: Final results from arches-2, double-blind period. Atherosclerosis. 395. 118515–118515.

10.

Rosenson, Robert S., Steven K. Baker, Maciej Banach, et al.. (2017). Optimizing Cholesterol Treatment in Patients With Muscle Complaints. Journal of the American College of Cardiology. 70(10). 1290–1301. 132 indexed citations

11.

Rosenson, Robert S., et al.. (2015). Underappreciated Opportunities for High-Density Lipoprotein Particles in Risk Stratification and Potential Targets of Therapy. Cardiovascular Drugs and Therapy. 29(1). 41–50. 12 indexed citations

12.

Rosenson, Robert S., Michael H. Davidson, Benjamin J. Hirsh, Sekar Kathiresan, & Daniel Gaudet. (2014). Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology. 64(23). 2525–2540. 189 indexed citations

13.

Santos‐Gallego, Carlos G., et al.. (2014). Beginning to Understand High-Density Lipoproteins. Endocrinology and Metabolism Clinics of North America. 43(4). 913–947. 82 indexed citations

14.

Kilgore, Meredith L., Paul Muntner, J. Michael Woolley, et al.. (2013). Discordance between high non-HDL cholesterol and high LDL-cholesterol among US adults. Journal of clinical lipidology. 8(1). 86–93. 32 indexed citations

15.

Rosenson, Robert S.. (2009). Role of the Endocannabinoid System in Abdominal Obesity and the Implications for Cardiovascular Risk. Cardiology. 114(3). 212–225. 12 indexed citations

16.

Rosenson, Robert S. & William H. Herman. (2008). Glycated proteins and cardiovascular disease in glucose intolerance and type 2 diabetes. Current Cardiovascular Risk Reports. 2(1). 43–46. 1 indexed citations

17.

Rosenson, Robert S.. (2007). Measure for measure—sugar or fats? Reconciling cardiovascular and diabetes risk with niacin therapy. Nature Clinical Practice Endocrinology & Metabolism. 3(2). 72–73. 2 indexed citations

18.

Bays, Harold, Lawrence Blonde, & Robert S. Rosenson. (2006). Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?. Expert Review of Cardiovascular Therapy. 4(6). 871–895. 84 indexed citations

19.

Wang, Sihe, Anders Boss, Kenneth R. Kensey, & Robert S. Rosenson. (2003). Variations of whole blood viscosity using Rheolog™—a new scanning capillary viscometer. Clinica Chimica Acta. 332(1-2). 79–82. 28 indexed citations

20.

Rosenson, Robert S.. (1993). Myocardial injury: The acute phase response and lipoprotein metabolism. Journal of the American College of Cardiology. 22(3). 933–940. 217 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact